CN110740751A - 用于治疗肺癌的结合物 - Google Patents

用于治疗肺癌的结合物 Download PDF

Info

Publication number
CN110740751A
CN110740751A CN201880035454.9A CN201880035454A CN110740751A CN 110740751 A CN110740751 A CN 110740751A CN 201880035454 A CN201880035454 A CN 201880035454A CN 110740751 A CN110740751 A CN 110740751A
Authority
CN
China
Prior art keywords
naltrexol
beta
vitamin
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880035454.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·达尔格利什
W·吕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ldn Pharmaceutical Co Ltd
Original Assignee
Ldn Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ldn Pharmaceutical Co Ltd filed Critical Ldn Pharmaceutical Co Ltd
Publication of CN110740751A publication Critical patent/CN110740751A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880035454.9A 2017-03-28 2018-03-28 用于治疗肺癌的结合物 Pending CN110740751A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704909.9A GB201704909D0 (en) 2017-03-28 2017-03-28 Cancer therapy
GB1704909.9 2017-03-28
PCT/GB2018/050820 WO2018178668A1 (en) 2017-03-28 2018-03-28 A combination for use in the treatment of lung cancer

Publications (1)

Publication Number Publication Date
CN110740751A true CN110740751A (zh) 2020-01-31

Family

ID=58688080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880035454.9A Pending CN110740751A (zh) 2017-03-28 2018-03-28 用于治疗肺癌的结合物

Country Status (6)

Country Link
US (1) US11304943B2 (https=)
EP (1) EP3600431B1 (https=)
JP (1) JP7282072B2 (https=)
CN (1) CN110740751A (https=)
GB (1) GB201704909D0 (https=)
WO (1) WO2018178668A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114533871A (zh) * 2020-11-19 2022-05-27 中国科学院上海营养与健康研究所 靶向plk3在防治皮肤增生性疾病中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294519A (zh) * 1999-02-18 2001-05-09 英法马有限公司 含有促进活性成分吸收活性的化合物的药物组合物
CN1802349A (zh) * 2003-06-11 2006-07-12 诺瓦西股份有限公司 用活性维生素d化合物和其他治疗一起治疗肺癌
CN101237886A (zh) * 2005-07-27 2008-08-06 奥雷西根治疗公司 产生重量减轻的组合物
CN101321554A (zh) * 2005-09-30 2008-12-10 Tti优而美株式会社 使用类阿片激动剂和/或类阿片拮抗剂的经皮药物输送系统、装置和方法
CN104936581A (zh) * 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法
WO2015189597A1 (en) * 2014-06-09 2015-12-17 Cancer Vaccine Institute Priming of cancer cells with low dose naltrexone
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
FR2759586B1 (fr) 1997-02-20 2000-01-14 Paul Trouillas Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
US6384044B1 (en) 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
EP1631543A1 (en) * 2003-06-11 2006-03-08 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US20090191185A1 (en) 2006-04-26 2009-07-30 The Uab Research Foundation Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8479760B2 (en) * 2010-06-30 2013-07-09 Easy Solutions Technologies, Inc. Air conditioner water pan drain line system
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294519A (zh) * 1999-02-18 2001-05-09 英法马有限公司 含有促进活性成分吸收活性的化合物的药物组合物
CN1802349A (zh) * 2003-06-11 2006-07-12 诺瓦西股份有限公司 用活性维生素d化合物和其他治疗一起治疗肺癌
CN101237886A (zh) * 2005-07-27 2008-08-06 奥雷西根治疗公司 产生重量减轻的组合物
CN101321554A (zh) * 2005-09-30 2008-12-10 Tti优而美株式会社 使用类阿片激动剂和/或类阿片拮抗剂的经皮药物输送系统、装置和方法
CN104936581A (zh) * 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法
WO2015189597A1 (en) * 2014-06-09 2015-12-17 Cancer Vaccine Institute Priming of cancer cells with low dose naltrexone
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
颜玲娣等: ""6β-纳曲醇单次和连续肌内注射给药在犬体内的药代动力学"", 《药学学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114533871A (zh) * 2020-11-19 2022-05-27 中国科学院上海营养与健康研究所 靶向plk3在防治皮肤增生性疾病中的应用

Also Published As

Publication number Publication date
GB201704909D0 (en) 2017-05-10
JP7282072B2 (ja) 2023-05-26
WO2018178668A1 (en) 2018-10-04
JP2020512408A (ja) 2020-04-23
US20200101064A1 (en) 2020-04-02
EP3600431B1 (en) 2022-11-23
US11304943B2 (en) 2022-04-19
EP3600431A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
EP2832358A1 (en) Pharmaceutical kit for use in the treatment of colon and colorectal cancer
US20190134034A1 (en) Method of Treating Liver Cancer
WO2018136010A1 (en) Combination therapy
US11351165B2 (en) Agent that increases the expression of the opioid kappa 1 for the treatment of cancer
Belda-Iniesta et al. Metformin: a new option in cancer treatment
Rajendran et al. Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer
WO2011092338A1 (en) Combined treatment of pancreatic cancer with gemcitabine and masitinib
Shadnoush et al. A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer
Wang et al. RETRACTED: Penfluridol triggers mitochondrial‐mediated apoptosis and suppresses glycolysis in colorectal cancer cells through down‐regulating hexokinase‐2
US10206920B2 (en) Pharmaceutical composition for treating cancer and a method of using the same
CN110740751A (zh) 用于治疗肺癌的结合物
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
TW202045155A (zh) 用於治療癌症之組合療法
Fei et al. Chemopreventive effects of rofecoxib and folic acid on gastric carcinogenesis induced by N‐methyl‐N′‐nitro‐N‐nitrosoguanidine in rats
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
CN111050801B (zh) 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
CN102781444A (zh) 用于治疗肝细胞癌的抗肿瘤剂或手术后辅助化学治疗剂
Gao et al. Endolysosomal cation channel MCOLN as the novel regulator of redox homeostasis
CN121925259A (zh) 血液癌的新型联合疗法
US8772284B2 (en) Method of treating cancer using combination of a bifunctional alkylating agent and DNA repair inhibitors
CN112168828A (zh) 一种egfr与cdk4/6小分子靶向药组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination